Rising Biosciences Receives FDA Clearance for TSW
Post# of 266
(Total Views: 728)
Posted On: 10/10/2018 9:21:55 AM
Rising Biosciences Receives FDA Clearance for TSW Pain Cream; Expedites Testing of CBD Only Variants of Cannophen™ and TSW Pain Cream Products
GlobeNewswire•October 10, 2018
RBII Seeks Corporate Registration in Canada Alongside Country’s Decision to Legalize Marijuana
SANDUSKY, Ohio, Oct. 10, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Rising Biosciences, Inc. (RBII) (“RBII” “the Company”), a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that we have completed, and passed all testing requirements for the FDA on its over-the-counter version of its TSW Pain Cream, and the product is now moving into production.
“The past 30 days have been very exciting for our industry,” states Rising Biosciences COO Arthur Hall. “ On September 21st, we completed our FDA testing on TSW, and last week, the DEA moved to place certain FDA approved CBD drugs down from Schedule I to Schedule V. It is the first time the agency has lowered any type of cannabis from Schedule 1, indicating the agency’s recognition of Cannabidiol as a viable medical treatment. Rising Biosciences is looking forward to working with the Canadian testing company ABICH Inc., who completed the FDA testing on our over-the-counter version of TSW Pain Cream for our testing needs on the CBD only variants of Cannophen and TSW Pain Cream.”
As well, on October 17th, 2018, Marijuana becomes legal in Canada as a result of ‘The Cannabis Act’, passed on June 3rd, 2018, marking Canada as the first G7 country to legalize Marijuana. Rising Biosciences has decided to seek registration as a foreign corporation in Canada to assertively expand operations there in wake of legalization.
“This is a special time for the Company and its Shareholders,” states Hall. “We have taken the company from dedicated vision to a fully integrated R&D, manufacturing and distribution, and are now ready for market. We are grateful for shareholder patience, and support through the monumental steps we’ve taken over the past year and a half, and we are now taking the Company to new heights with some major updates to follow.”
$RBII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
CONTACT INFO: For Investor Inquiries: IR@risingbiosciences.com
GlobeNewswire•October 10, 2018
RBII Seeks Corporate Registration in Canada Alongside Country’s Decision to Legalize Marijuana
SANDUSKY, Ohio, Oct. 10, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Rising Biosciences, Inc. (RBII) (“RBII” “the Company”), a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that we have completed, and passed all testing requirements for the FDA on its over-the-counter version of its TSW Pain Cream, and the product is now moving into production.
“The past 30 days have been very exciting for our industry,” states Rising Biosciences COO Arthur Hall. “ On September 21st, we completed our FDA testing on TSW, and last week, the DEA moved to place certain FDA approved CBD drugs down from Schedule I to Schedule V. It is the first time the agency has lowered any type of cannabis from Schedule 1, indicating the agency’s recognition of Cannabidiol as a viable medical treatment. Rising Biosciences is looking forward to working with the Canadian testing company ABICH Inc., who completed the FDA testing on our over-the-counter version of TSW Pain Cream for our testing needs on the CBD only variants of Cannophen and TSW Pain Cream.”
As well, on October 17th, 2018, Marijuana becomes legal in Canada as a result of ‘The Cannabis Act’, passed on June 3rd, 2018, marking Canada as the first G7 country to legalize Marijuana. Rising Biosciences has decided to seek registration as a foreign corporation in Canada to assertively expand operations there in wake of legalization.
“This is a special time for the Company and its Shareholders,” states Hall. “We have taken the company from dedicated vision to a fully integrated R&D, manufacturing and distribution, and are now ready for market. We are grateful for shareholder patience, and support through the monumental steps we’ve taken over the past year and a half, and we are now taking the Company to new heights with some major updates to follow.”
$RBII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
CONTACT INFO: For Investor Inquiries: IR@risingbiosciences.com
(1)
(0)